Oseni (Alogliptin Benz/Pioglitazone) Patent Expiration, LOE Window & CMS Spending
Oseni (Alogliptin Benz/Pioglitazone) by Takeda: FDA Orange Book core substance LOE 2028-06-27 (last listed 2029-06-04), 0 AB generics, $79K 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Takeda |
| FDA Application & Pathway | N022426 (NDA) |
| Exclusivity / Cliff Horizon | Near-Term Cliff (2028-2030) |
| Core Active-Ingredient LOE Date | 2028-06-27 |
| Last Listed Patent or Exclusivity Date | 2029-06-04 |
| Orange Book Patents (*PED Extensions) | 2 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $79K |
| 2024 Medicare Part D Spend | $49K |
| 2024 Medicaid Spend | $30K |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Takeda across sibling Meru public-data platforms.